Wei Sang

16PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursMolecular targetsSystems physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 22, 2026
Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

|May 21, 2026
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

|Aug 23, 2025
Prognostic value of the co-stimulatory molecule OX40 expression in Extranodal Natural Killer/T-cell Lymphoma.

Haiyan Zhang, Yujie Li, Qing Zhang

|May 09, 2025
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study.

Si-Yuan Chen, Peng-Peng Xu, Ru Feng

|Mar 16, 2025
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.

Sha Ma, Jieyun Xia, Miao Zhang

|Jun 17, 2024
Clinicopathological analysis of immunohistochemical CD47 and signal-regulatory protein-α expression in Extranodal Natural killer/T-cell lymphoma.

Zaixiang Tan, Qing Zhang, Ying Wang

Pageof 3

Frequent Collaborators

4 joint publications

Kailin Xu

3 joint publications

Jiang Cao

3 joint publications

Feng Zhu

3 joint publications

Ziyuan Shen